Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Niemann-Pick type C disease
Pharma
Zevra CEO drafts big ambitions for Miplyffa's US adoption curve
With Miplyffa, Zevra's CEO wants to transform the American treatment landscape for Niemann-Pick disease type C into one resembling Europe’s.
Fraiser Kansteiner
Jun 3, 2026 11:17am
Zevra embarks on diagnosis push as Miplyffa launch gains steam
Mar 13, 2025 11:24am
Zevra lines up $150M from sale of PRV tied to Miplyffa approval
Feb 27, 2025 9:58am
Zevra pegs Miplyffa as 'cornerstone' of Niemann-Pick treatment
Oct 4, 2024 6:45am
IntraBio hits the ground running with new rare disease launch
Sep 30, 2024 3:25pm
IntraBio snags FDA nod in rare disease just days after Zevra
Sep 25, 2024 9:50am
